Because of the interactions among β-amyloid, α-synuclein, and NFT-tau,3,4 it is possible that targeting β-amyloid alone might contribute to overall pathologic progression and functional improvement in probable DLB patients. The gene discussed is MAPT; the disease is Lewy body dementia.